The Global Minimal Residual Disease Testing Market Size is expected to reach USD 4.38 billion by 2032, at a CAGR of 11.7% during the forecast period 2023 to 2032. Minimal Residual Disease (MRD) testing is a sensitive diagnostic method used to detect trace amounts of cancer cells remaining in patients after treatment.